Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
종목 코드 SEER
회사 이름Seer Inc
상장일Dec 04, 2020
CEODr. Omid C. Farokhzad, M.D.
직원 수134
유형Ordinary Share
회계 연도 종료Dec 04
주소3800 Bridge Parkway, Suite 102
도시REDWOOD CITY
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호94065
전화16504530000
웹사이트https://seer.bio/
종목 코드 SEER
상장일Dec 04, 2020
CEODr. Omid C. Farokhzad, M.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음